Johnson & Johnson Completes Catheter Portfolio

Johnson & Johnson has announced the U.S. launch of CEREGLIDE™ 42 and CEREGLIDE™ 57 aspiration catheters, along with the INNERGLIDE™ 7 delivery aid, as the latest additions to its aspiration-first stroke portfolio. These devices complete the CEREGLIDE™ family and are designed to help physicians reach and remove distal* clots more consistently, while simplifying procedural decisions and supporting performance across a broad range of ischemic stroke cases.

“We designed this multi-axial system to address procedural challenges physicians face when treating stroke,” said Christian Cuzick, Worldwide President, Neurovascular, MedTech, Johnson & Johnson. “With this expanded portfolio, we’re simplifying decisions, enhancing consistency across device sizes, and reinforcing our commitment to helping improve patient outcomes.”

CEREGLIDE™ 42 and CEREGLIDE™ 57 are built with a proprietary, variable-stiffness¹ construction that provides flexible¹ distal* navigation and supportive proximal control. Both catheters are intended to integrate seamlessly into existing neurointerventional workflows, offering:

• Hydrophilic coating¹ for reduced friction in tortuous anatomy
• Radiopaque (based on benchmark testing) tip marker for fluoroscopic visibility
• Easily track to the M2** with TruCourse™ Technology

“Accessing distal occlusions remains one of the biggest technical challenges we face, especially in smaller or more tortuous vessels,” said Ameer E. Hassan², DO, FAHA, FSVIN, Neuroscience Institute, Valley Baptist Medical Center, Harlingen, Texas. “In my experience, CEREGLIDE 42 and 57 track reliably while maintaining strong proximal support, even over multiple passes.³ That balance of flexibility and control gives me greater confidence when performing aspiration-first thrombectomy in more complex anatomy.”

INNERGLIDE™ 7 is a delivery aid designed to support the advancement of large-bore catheters like CEREGLIDE™ 71 to distal* clot locations***. It features a hydrophilic-coated shaft, 1.5 cm soft distal tip, and compatibility with 0.024” guidewires, offering added control and support during complex device delivery.

“Reaching the M2 segment with large-bore aspiration systems can be technically demanding,” said Dr. Hassan. “INNERGLIDE 7 provides the additional support needed to consistently deliver CEREGLIDE 71 into more distal targets with smoother navigation and less resistance. I am a firm believer in delivery catheter technology like Innerglide.”

The CEREGLIDE™ family of catheters now includes 42, 57, and 71 aspiration catheters, providing a range of catheters designed for performance, consistency, and compatibility across procedures.

Footnotes

*Distal refers to the M2

**Based on benchtop testing

***Based on preclinical testing and preclinical testing may not be indicative of clinical results

  i. With the CEREGLIDE family of catheters eliminating ID/OD compatibility concerns

1.  501331844/Verification & Validation – CG42+CG57 Characterization Report. Version A.8. February 29, 2024.
2. Dr. Ameer E. Hassan serves as a consultant for Johnson & Johnson but was not compensated for this announcement
3. This intermediate catheter has not been evaluated for more than 3 clot retrieval attempts using direct aspiration

Source: Johnson & Johnson

The post Johnson & Johnson Completes Catheter Portfolio appeared first on Surgical Robotics Technology.